What Happened?
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 8.7% in the pre-market session after the company reported weak fourth-quarter results: Medpace's full-year revenue, EPS, and EBITDA guidance fell short of Wall Street's estimates. The weaker-than-expected outlook suggests slowing business momentum, as reflected in the declining book-to-bill ratio of 0.99x. On the other hand, the company exceeded analysts' EPS and EBITDA expectations this quarter.Overall, this quarter could have been better.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Medpace? Access our full analysis report here, it’s free.
What The Market Is Telling Us
Medpace’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
Medpace is down 1.8% since the beginning of the year, and at $328.72 per share, it is trading 28.1% below its 52-week high of $457.29 from July 2024. Investors who bought $1,000 worth of Medpace’s shares 5 years ago would now be looking at an investment worth $3,392.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
